 | Up a level |
Mark, M; Rusakiewicz, S; Früh, M; Hayoz, S; Grosso, F; Pless, M; Zucali, P; Ceresoli, G L; Maconi, A; Schneider, M; Froesch, P; Tarussio, D; Benedetti, F; Dagher, J; Kandalaft, L; von Moos, R; Tissot-Renaud, S; Schmid, S; Metaxas, Y (2022). Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO open, 7(3), p. 100446. BMJ 10.1016/j.esmoop.2022.100446
Rosell, Rafael; Dafni, Urania; Felip, E; Curioni-Fontecedro, A; Gautschi, O; Peters, S; Massuti, B; Palmero, R; Aix, SP; Carcereny, E; Früh, M; Pless, M; Popat, S; Kotsakis, A; Cuffe, S; Bidoli, P; Favaretto, A; Froesch, P; Reguart, N; Puente, J; ... (2017). Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. The lancet. Respiratory medicine, 5(5), pp. 435-444. Elsevier 10.1016/S2213-2600(17)30129-7
Gautschi, O; Li, Q; Matter-Walstra, K; Betticher, D; Frueh, M; Rauch, Daniel; Pless, M; Froesch, P; Mach, N; Ochsenbein, Adrian (2016). 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial. Journal of thoracic oncology, 11(4Suppl), S120-S120. Elsevier 10.1016/S1556-0864(16)30253-2
